{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:44:14Z","timestamp":1792619054651,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.urolonc.2020.12.021","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:34:23Z","timestamp":1625013263000},"page":"731.e1-731.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comprehensive genomic profiling of histologic subtypes of urethral carcinomas"],"prefix":"10.1016","volume":"39","author":[{"given":"Joseph","family":"Jacob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Mollapour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Talal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Anne","family":"Vergilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Killian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakti","family":"Ramkissoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Severson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Hemmerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clair","family":"Edgerly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Madison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Venstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanth","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Elvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Schrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Danziger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Pavlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennady","family":"Bratslavsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.12.021_bib0001","series-title":"Campbell's urology","first-page":"1441","article-title":"Benign and malignant tumors of the male and female urethra","author":"Hopkins","year":"1986"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0002","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.hoc.2012.08.006","article-title":"Urethral cancer","volume":"26","author":"Grivas","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0003","first-page":"147","article-title":"Primary carcinomas of the urethra","volume":"14","author":"Amin","year":"1997","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0004","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.urology.2006.08.1057","article-title":"Incidence of primary urethral carcinoma in the United States","volume":"68","author":"Swartz","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0005","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ucl.2010.04.011","article-title":"Surgery for urethral cancer","volume":"37","author":"Karnes","year":"2010","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0006","article-title":"The epidemiology and role of surgery in the treatment of urethral clear cell carcinoma","author":"Patel","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0007","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.urology.2012.02.058","article-title":"Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis","volume":"80","author":"Champ","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0008","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/cncr.25787","article-title":"Prognostic factors in male urethral cancer","volume":"117","author":"Rabbani","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0009","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.coc.0000037764.72722.07","article-title":"Retrospective study of the treatment of urethral cancer","volume":"26","author":"Eng","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0010","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.euf.2019.07.001","article-title":"current disease management of primary urethral carcinoma","volume":"5","author":"Janisch","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bju.12630","article-title":"Management of advanced primary urethral carcinomas","volume":"114","author":"Dayyani","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0012","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.urolonc.2012.01.011","article-title":"Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists","volume":"31","author":"Dayyani","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0013","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2013.03.044","article-title":"European Association of Urology. EAU guidelines on primary urethral carcinoma","volume":"64","author":"Gakis","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0014","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"Database issue","key":"10.1016\/j.urolonc.2020.12.021_bib0015","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: exploring the world's knowledge of somatic mutations in human cancer","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0016","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0017","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A Novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0018","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0019","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13046-019-1192-1","article-title":"PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer","volume":"38","author":"Chen","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0020","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/14728222.2019.1654458","article-title":"Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers","volume":"23","author":"Przybycinski","year":"2019","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0021","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcancer.2015.08.006","article-title":"The biological complexity of urothelial carcinoma: insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches","volume":"35","author":"Grivas","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0022","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1126\/science.aaw9032","article-title":"Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors","volume":"366","author":"Vasan","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0023","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ajpath.2013.11.023","article-title":"Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing","volume":"184","author":"Mehra","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0024","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/modpathol.2013.135","article-title":"Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy","volume":"27","author":"Ross","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/PAP.0000000000000252","article-title":"Updates on the genomics of bladder cancer and novel molecular taxonomy","volume":"27","author":"l-Ahmadie","year":"2020","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0026","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-3-319-93339-9_12","article-title":"The cancer genome atlas project in bladder cancer","volume":"175","author":"Rodriguez-Vida","year":"2018","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0027","doi-asserted-by":"crossref","first-page":"52442","DOI":"10.18632\/oncotarget.9449","article-title":"Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma","volume":"7","author":"Joshi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0028","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/carcin\/bgu064","article-title":"Genome-wide interaction study of smoking and bladder cancer risk","volume":"35","author":"Figueroa","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0029","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.18632\/oncotarget.27287","article-title":"Tumor mutational burden in lung cancer: a systematic literature review","volume":"10","author":"Willis","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jss.2018.07.007","article-title":"Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma","volume":"230","author":"Nagahashi","year":"2018","journal-title":"J Surg Res"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0031","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0032","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1158\/1078-0432.CCR-09-0898","article-title":"Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer","volume":"15","author":"Platt","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0033","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1158\/1535-7163.MCT-10-0994","article-title":"PIK3CA mutations in patients with advanced cancers treated with PI3K\/AKT\/mTOR axis inhibitors","volume":"10","author":"Janku","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0034","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40265-019-01161-6","article-title":"Alpelisib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0035","doi-asserted-by":"crossref","first-page":"x27","DOI":"10.1093\/annonc\/mdz280","article-title":"Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors","volume":"30","author":"Brand\u00e3o","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0036","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1158\/1078-0432.CCR-18-0613","article-title":"Phase II study of taselisib (GDC-0032) in combination with fulvestrant in patients with HER2-negative, hormone receptor-positive advanced breast cancer","volume":"24","author":"Dickler","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0037","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/157015912804499537","article-title":"mTOR inhibitors in tuberous sclerosis complex","volume":"10","author":"Curatolo","year":"2012","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms20030755","article-title":"mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy","volume":"20","author":"Tian","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0039","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000443280","article-title":"Complete and durable remission of human epidermal growth factor receptor 2-positive metastatic urothelial carcinoma following third-line treatment with trastuzumab and gemcitabine","volume":"100","author":"Wezel","year":"2018","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0040","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.6004\/jnccn.2015.0131","article-title":"HER2-mutated breast cancer responds to treatment with single-agent neratinib, a second-generation HER2\/EGFR tyrosine kinase inhibitor","volume":"13","author":"Ben-Baruch","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0041","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1040-8428(03)00067-2","article-title":"Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family","volume":"46","author":"Bellmunt","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0042","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40265-019-01235-5","article-title":"Poly (ADP-ribose) polymerase inhibition in patients with breast cancer and BRCA 1 and 2 mutations","volume":"80","author":"Jerez","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0043","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-018-3532-9","article-title":"PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer","volume":"81","author":"Morgan","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0044","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.ejca.2014.07.004","article-title":"Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer","volume":"50","author":"Garc\u00eda-Parra","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6879","article-title":"Association of survival and Immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis","volume":"2","author":"Yu","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0046","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00428-012-1363-3","article-title":"Histology and immunohistochemistry of clear cell adenocarcinoma of the urethra: histogenesis and diagnostic problems","volume":"462","author":"Alexiev","year":"2013","journal-title":"Virchows Arch"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0047","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.humpath.2009.10.011","article-title":"Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma","volume":"41","author":"Herawi","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0048","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1016\/j.juro.2008.09.064","article-title":"Clear cell adenocarcinoma of the bladder and urethra","volume":"180","author":"Bagby","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0049","first-page":"513","article-title":"Clear cell adenocarcinoma of the urethra: a clinicopathologic analysis of 19 cases","volume":"9","author":"Oliva","year":"1996","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0050","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.clgc.2011.10.002","article-title":"Metastatic clear cell adenocarcinoma of the urethra in a male patient: report of a case","volume":"10","author":"Liu","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0051","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4103\/0377-4929.97895","article-title":"Clear cell adenocarcinoma of the male urethral tract","volume":"55","author":"Gandhi","year":"2012","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0052","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1442-2042.2003.00629.x","article-title":"Clear cell adenocarcinoma of the male urethra","volume":"10","author":"G\u00f6gus","year":"2003","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2020.12.021_bib0053","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00428-019-02634-5","article-title":"Molecular profiling of clear cell adenocarcinoma of the urinary tract","volume":"475","author":"Lin","year":"2019","journal-title":"Virchows Arch"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920306505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920306505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:20:58Z","timestamp":1761042058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920306505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1078143920306505"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.12.021","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive genomic profiling of histologic subtypes of urethral carcinomas","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}